Merck's View On The Challenges Of Ebola Vaccination In The DRC
With the latest Ebola outbreak threatening to spread across the Democratic Republic of Congo and beyond, efforts are being stepped up to vaccinate the at-risk population and health workers with Merck Sharp & Dohme’s experimental vaccine, V920. MSD’s Mel Kohn spoke to the Pink Sheet about the development of the vaccine, the experience gained from its use to date, and the difficulties involved in getting the vaccine to those who need it.
You may also be interested in...
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.
People at risk of contracting the Ebola virus in the latest outbreak in the Democractic Republic of Congo are to have another vaccination option in the form of Janssen’s experimental prime-boost vaccine regimen, Ad26.ZEBOV/MVA-BN.